Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H902
UPID:
REEP1_HUMAN
Alternative names:
Spastic paraplegia 31 protein
Alternative UPACC:
Q9H902; B7Z4D7; B7Z4F2; B7Z5R9; D6W5M2; Q53TI0
Background:
Receptor expression-enhancing protein 1, also known as Spastic paraplegia 31 protein, plays a crucial role in endoplasmic reticulum network formation, shaping, and remodeling. It connects ER tubules to the cytoskeleton and may enhance cell surface expression of odorant receptors. Additionally, it is implicated in long-term axonal maintenance.
Therapeutic significance:
Linked to diseases such as Spastic paraplegia 31, autosomal dominant, Neuronopathy, distal hereditary motor, 5B, and Distal spinal muscular atrophy, autosomal recessive, 6, understanding the role of Receptor expression-enhancing protein 1 could open doors to potential therapeutic strategies.